Literature DB >> 19182537

Autophagy induction by trehalose counteracts cellular prion infection.

Yasmine Aguib1, Andreas Heiseke, Sabine Gilch, Constanze Riemer, Michael Baier, Hermann M Schätzl, Alexa Ertmer.   

Abstract

Prion diseases are fatal neurodegenerative and infectious disorders for which no therapeutic or prophylactic regimens exist. In search of cellular mechanisms that play a role in prion diseases and have the potential to interfere with accumulation of intracellular pathological prion protein (PrP(Sc)), we investigated the autophagic pathway and one of its recently published inducers, trehalose. Trehalose, an alpha-linked disaccharide, has been shown to accelerate clearance of mutant huntingtin and alpha-synuclein by activating autophagy, mainly in an mTOR-independent manner. Here, we demonstrate that trehalose can significantly reduce PrP(Sc) in a dose- and time-dependent manner while at the same time it induces autophagy in persistently prion-infected neuronal cells. Inhibition of autophagy, either pharmacologically by known autophagy inhibitors like 3-methyladenine, or genetically by siRNA targeting Atg5, counteracted the anti-prion effect of trehalose. Hence, we provide direct experimental evidence that induction of autophagy mediates enhanced cellular degradation of prions. Similar results were obtained with rapamycin, a known inducer of autophagy, and imatinib, which has been shown to activate autophagosome formation. While induction of autophagy resulted in reduction of PrP(Sc), inhibition of autophagy increased the amounts of cellular PrP(Sc), suggesting that autophagy is involved in the physiological degradation process of cellular PrP(Sc). Preliminary in vivo studies with trehalose in intraperitoneally prion-infected mice did not result in prolongation of incubation times, but demonstrated delayed appearance of PrP(Sc) in the spleen. Overall, our study provides the first experimental evidence for the impact of autophagy in yet another type of neurodegenerative disease, namely prion disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19182537     DOI: 10.4161/auto.5.3.7662

Source DB:  PubMed          Journal:  Autophagy        ISSN: 1554-8627            Impact factor:   16.016


  89 in total

1.  Abrogation of complex glycosylation by swainsonine results in strain- and cell-specific inhibition of prion replication.

Authors:  Shawn Browning; Christopher A Baker; Emery Smith; Sukhvir P Mahal; Maria E Herva; Cheryl A Demczyk; Jiali Li; Charles Weissmann
Journal:  J Biol Chem       Date:  2011-09-19       Impact factor: 5.157

Review 2.  Prions on the move.

Authors:  Charles Weissmann; Jiali Li; Sukhvir P Mahal; Shawn Browning
Journal:  EMBO Rep       Date:  2011-10-28       Impact factor: 8.807

3.  Trehalose Inhibits Human Immunodeficiency Virus Type 1 Infection in Primary Human Macrophages and CD4+ T Lymphocytes through Two Distinct Mechanisms.

Authors:  Pratima Rawat; Simson Hon; Carmen Teodorof-Diedrich; Stephen A Spector
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

Review 4.  Interplay of endoplasmic reticulum stress and autophagy in neurodegenerative disorders.

Authors:  Yu Cai; Jyothi Arikkath; Lu Yang; Ming-Lei Guo; Palsamy Periyasamy; Shilpa Buch
Journal:  Autophagy       Date:  2016       Impact factor: 16.016

Review 5.  Review: autophagy and neurodegeneration: survival at a cost?

Authors:  S J Cherra; R K Dagda; C T Chu
Journal:  Neuropathol Appl Neurobiol       Date:  2010-02-19       Impact factor: 8.090

6.  Protecting activity of desiccated enzymes.

Authors:  Samantha Piszkiewicz; Kathryn H Gunn; Owen Warmuth; Ashlee Propst; Aakash Mehta; Kenny H Nguyen; Elizabeth Kuhlman; Alex J Guseman; Samantha S Stadmiller; Thomas C Boothby; Saskia B Neher; Gary J Pielak
Journal:  Protein Sci       Date:  2019-03-30       Impact factor: 6.725

Review 7.  Lysosomal Quality Control in Prion Diseases.

Authors:  Priyanka Majumder; Oishee Chakrabarti
Journal:  Mol Neurobiol       Date:  2017-04-18       Impact factor: 5.590

Review 8.  Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases.

Authors:  Maurizio Renna; Maria Jimenez-Sanchez; Sovan Sarkar; David C Rubinsztein
Journal:  J Biol Chem       Date:  2010-02-10       Impact factor: 5.157

9.  Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease.

Authors:  Patricia Spilman; Natalia Podlutskaya; Matthew J Hart; Jayanta Debnath; Olivia Gorostiza; Dale Bredesen; Arlan Richardson; Randy Strong; Veronica Galvan
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

10.  The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease.

Authors:  Jonathan H Fox; Teal Connor; Vanita Chopra; Kate Dorsey; Jibrin A Kama; Dorothee Bleckmann; Claudia Betschart; Daniel Hoyer; Stefan Frentzel; Marian Difiglia; Paolo Paganetti; Steven M Hersch
Journal:  Mol Neurodegener       Date:  2010-06-22       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.